This clinical trial is focused on studying a type of cancer called Peripheral T-Cell Lymphoma, which is a rare and aggressive form of blood cancer that affects the lymphatic system. The study is investigating a treatment using a medication called Valemetostat Tosylate, which is taken as a film-coated tablet. The purpose of the study is to evaluate how well this medication works and how safe it is for patients who have this type of lymphoma that has either returned after treatment or has not responded to previous treatments.

Participants in the study will receive Valemetostat Tosylate as a monotherapy, meaning it is the only treatment they will be given. The study will follow a single-arm design, which means all participants will receive the same treatment without a comparison group. The medication will be administered orally, and the study will monitor the participants over a period of time to observe their response to the treatment and any side effects they may experience. The study aims to gather information on the effectiveness of the treatment in reducing the cancer and improving the patients’ condition.

Throughout the study, participants will undergo regular assessments to check their health status and the progress of the treatment. These assessments may include medical tests and imaging techniques like computed tomography (CT) scans to measure the size of the cancer. The study will also track any adverse effects or changes in the participants’ health to ensure the treatment is safe. The ultimate goal is to determine if Valemetostat Tosylate can be a beneficial treatment option for patients with relapsed or refractory Peripheral T-Cell Lymphoma.